Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28


Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.

Han K, Capitano B, Bies R, Potoski BA, Husain S, Gilbert S, Paterson DL, McCurry K, Venkataramanan R.

Antimicrob Agents Chemother. 2010 Oct;54(10):4424-31. doi: 10.1128/AAC.00504-10. Epub 2010 Aug 2.


Distribution of voriconazole in seven body fluids of adult horses after repeated oral dosing.

Passler NH, Chan HM, Stewart AJ, Duran SH, Welles EG, Lin HC, Ravis WR.

J Vet Pharmacol Ther. 2010 Feb;33(1):35-41. doi: 10.1111/j.1365-2885.2009.01099.x.


Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL.

Antimicrob Agents Chemother. 2009 Dec;53(12):5102-7. doi: 10.1128/AAC.01042-09. Epub 2009 Sep 21.


Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.

Weiler S, Falkensammer G, Hammerer-Lercher A, Anliker M, Vogelsinger H, Joannidis M, Dunzendorfer S, Stein M, Bellmann R.

Antimicrob Agents Chemother. 2009 Nov;53(11):4934-7. doi: 10.1128/AAC.00796-09. Epub 2009 Aug 24.


Concentrations of voriconazole in healthy and inflamed lung in rats.

Joukhadar C, Thallinger C, Pöppl W, Kovar F, Konz KH, Joukhadar SM, Traunmüller F.

Antimicrob Agents Chemother. 2009 Jun;53(6):2684-6. doi: 10.1128/AAC.00885-08. Epub 2009 Mar 30.


Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens.

Burhenne J, Haefeli WE, Hess M, Scope A.

J Avian Med Surg. 2008 Sep;22(3):199-207.


Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.

Lass-Flörl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, Fille M.

Antimicrob Agents Chemother. 2008 Oct;52(10):3637-41. doi: 10.1128/AAC.00662-08. Epub 2008 Aug 11.


Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, Pappas PG, Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G, Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA, Muñoz P, Odds FC, Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel JD, Sorrell TC, Viscoli C, Wingard JR, Zaoutis T, Bennett JE; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Clin Infect Dis. 2008 Jun 15;46(12):1813-21. doi: 10.1086/588660.


Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America.

Clin Infect Dis. 2008 Feb 1;46(3):327-60. doi: 10.1086/525258. No abstract available.


Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O.

Clin Infect Dis. 2008 Jan 15;46(2):201-11. doi: 10.1086/524669.


Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman.

Elter T, Sieniawski M, Gossmann A, Wickenhauser C, Schröder U, Seifert H, Kuchta J, Burhenne J, Riedel KD, Fätkenheuer G, Cornely OA.

Int J Antimicrob Agents. 2006 Sep;28(3):262-5.


Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen.

Capitano B, Potoski BA, Husain S, Zhang S, Paterson DL, Studer SM, McCurry KR, Venkataramanan R.

Antimicrob Agents Chemother. 2006 May;50(5):1878-80.


Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion.

Vogelsinger H, Weiler S, Djanani A, Kountchev J, Bellmann-Weiler R, Wiedermann CJ, Bellmann R.

J Antimicrob Chemother. 2006 Jun;57(6):1153-60. Epub 2006 Apr 20.


Voriconazole therapeutic drug monitoring.

Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D.

Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2.


Pericardial and pleural diffusion of voriconazole during disseminated invasive aspergillosis: report of a case with successful outcome.

Poupelin JC, Philit F, Richard JC, Badet M, Lemasson S, Bayle F, Guérin C.

Intensive Care Med. 2006 Jun;32(6):939-40. Epub 2006 Mar 11. No abstract available.


Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes.

Ballesta S, García I, Perea EJ, Pascual A.

J Antimicrob Chemother. 2005 May;55(5):785-7. Epub 2005 Apr 11.


Pharmacokinetics of voriconazole in the cerebrospinal fluid of an immunocompromised patient with a brain abscess due to Aspergillus fumigatus.

Denes E, Pichon N, Debette-Gratien M, Bouteille B, Gaulier JM.

Clin Infect Dis. 2004 Aug 15;39(4):603-4. No abstract available.

Items per page

Supplemental Content

Support Center